AU2015318207B2 - Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer - Google Patents

Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer Download PDF

Info

Publication number
AU2015318207B2
AU2015318207B2 AU2015318207A AU2015318207A AU2015318207B2 AU 2015318207 B2 AU2015318207 B2 AU 2015318207B2 AU 2015318207 A AU2015318207 A AU 2015318207A AU 2015318207 A AU2015318207 A AU 2015318207A AU 2015318207 B2 AU2015318207 B2 AU 2015318207B2
Authority
AU
Australia
Prior art keywords
vegf
patient
domain
mcrc
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015318207A
Other languages
English (en)
Other versions
AU2015318207A1 (en
Inventor
Bo Gao
Israel Lowy
Tasha Nicholle Sims
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2015318207A1 publication Critical patent/AU2015318207A1/en
Application granted granted Critical
Publication of AU2015318207B2 publication Critical patent/AU2015318207B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015318207A 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer Active AU2015318207B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051091P 2014-09-16 2014-09-16
US62/051,091 2014-09-16
US201562099630P 2015-01-05 2015-01-05
US62/099,630 2015-01-05
PCT/US2015/049279 WO2016044041A1 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Publications (2)

Publication Number Publication Date
AU2015318207A1 AU2015318207A1 (en) 2017-04-06
AU2015318207B2 true AU2015318207B2 (en) 2021-11-04

Family

ID=54207741

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015318207A Active AU2015318207B2 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Country Status (12)

Country Link
US (2) US10525104B2 (enExample)
EP (1) EP3194974B1 (enExample)
JP (1) JP6692358B2 (enExample)
KR (1) KR102471057B1 (enExample)
CN (1) CN107076749B (enExample)
AU (1) AU2015318207B2 (enExample)
CA (1) CA2960890A1 (enExample)
EA (1) EA036671B1 (enExample)
IL (1) IL250905B (enExample)
MX (1) MX382673B (enExample)
WO (1) WO2016044041A1 (enExample)
ZA (1) ZA201701664B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11699527B2 (en) 2013-03-14 2023-07-11 Otraces, Inc. Method for improving disease diagnosis using measured analytes
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6952056B2 (ja) 2016-01-22 2021-10-20 オートレイシーズ, インク.Otraces, Inc. 疾患診断を改善するシステム及び方法
CA3058129C (en) * 2017-03-31 2023-04-18 Hirotsu Bio Science Inc. Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
JP2022541689A (ja) * 2019-07-13 2022-09-26 オートレイシーズ，インク． 腫瘍微小環境活性蛋白質を用いる種々の疾患の診断の改善
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
IN2012DN02046A (enExample) * 2009-08-14 2015-08-21 Allergan Inc
CN102711830A (zh) 2010-01-19 2012-10-03 霍夫曼-拉罗奇有限公司 用于贝伐单抗联合疗法的基于肿瘤组织的生物标志
SG10201505593VA (en) * 2010-07-19 2015-09-29 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
George, M. et al., ‘VEGF-A, VEGF-C, and VEGF-D in Colorectal Cancer Progression’, Neoplasia. 2001, vol.3, DOI: 10.1038/sj.neo.7900186 *
Hidetoshi Hayashi ET AL, "Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma", Oncotarget, United States, (2014-05-15), page 2588, *

Also Published As

Publication number Publication date
EA036671B1 (ru) 2020-12-07
WO2016044041A1 (en) 2016-03-24
AU2015318207A1 (en) 2017-04-06
EA201790549A1 (ru) 2017-07-31
US10525104B2 (en) 2020-01-07
CN107076749B (zh) 2020-12-29
EP3194974B1 (en) 2019-10-23
MX382673B (es) 2025-03-13
ZA201701664B (en) 2018-05-30
MX2017003387A (es) 2018-01-30
JP2017530372A (ja) 2017-10-12
JP6692358B2 (ja) 2020-05-13
IL250905B (en) 2019-12-31
KR102471057B1 (ko) 2022-11-28
IL250905A0 (en) 2017-04-30
CA2960890A1 (en) 2016-03-24
KR20170055972A (ko) 2017-05-22
EP3194974A1 (en) 2017-07-26
CN107076749A (zh) 2017-08-18
US20200129589A1 (en) 2020-04-30
US20170281725A1 (en) 2017-10-05
US11439683B2 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
US11439683B2 (en) Anti-angiogenic therapy of metastatic colorectal cancer
AU2011281700B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
JP6055764B2 (ja) 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
KR101523419B1 (ko) 베바시주맙 병용 치료법을 위한 종양 조직 기본 바이오마커
US20180136216A1 (en) Biomarkers for a Combination Therapy Comprising Lenvatinib and Everolimus
AU2017248061A1 (en) Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to cancer treatment
US11415584B2 (en) Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug
WO2016115149A1 (en) Neuropilin-1 as a serum based biomarker
AU2016247169A1 (en) Tumor tissue based biomarkers for bevacizumab combination therapies
HK1198063A (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
AU2014208271A1 (en) Tumor tissue based biomarkers for bevacizumab combination therapies
HK1184854B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)